Correlation Between Crispr Therapeutics and Alnylam Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Crispr Therapeutics and Alnylam Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crispr Therapeutics and Alnylam Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Crispr Therapeutics AG and Alnylam Pharmaceuticals, you can compare the effects of market volatilities on Crispr Therapeutics and Alnylam Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crispr Therapeutics with a short position of Alnylam Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crispr Therapeutics and Alnylam Pharmaceuticals.
Diversification Opportunities for Crispr Therapeutics and Alnylam Pharmaceuticals
0.18 | Correlation Coefficient |
Average diversification
The 3 months correlation between Crispr and Alnylam is 0.18. Overlapping area represents the amount of risk that can be diversified away by holding Crispr Therapeutics AG and Alnylam Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Alnylam Pharmaceuticals and Crispr Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crispr Therapeutics AG are associated (or correlated) with Alnylam Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Alnylam Pharmaceuticals has no effect on the direction of Crispr Therapeutics i.e., Crispr Therapeutics and Alnylam Pharmaceuticals go up and down completely randomly.
Pair Corralation between Crispr Therapeutics and Alnylam Pharmaceuticals
Given the investment horizon of 90 days Crispr Therapeutics AG is expected to under-perform the Alnylam Pharmaceuticals. In addition to that, Crispr Therapeutics is 1.27 times more volatile than Alnylam Pharmaceuticals. It trades about -0.02 of its total potential returns per unit of risk. Alnylam Pharmaceuticals is currently generating about 0.02 per unit of volatility. If you would invest 27,155 in Alnylam Pharmaceuticals on November 1, 2024 and sell it today you would earn a total of 244.00 from holding Alnylam Pharmaceuticals or generate 0.9% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Crispr Therapeutics AG vs. Alnylam Pharmaceuticals
Performance |
| Timeline |
| Crispr Therapeutics |
| Alnylam Pharmaceuticals |
Crispr Therapeutics and Alnylam Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Crispr Therapeutics and Alnylam Pharmaceuticals
The main advantage of trading using opposite Crispr Therapeutics and Alnylam Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crispr Therapeutics position performs unexpectedly, Alnylam Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will offset losses from the drop in Alnylam Pharmaceuticals' long position.| Crispr Therapeutics vs. Beam Therapeutics | Crispr Therapeutics vs. Editas Medicine | Crispr Therapeutics vs. Caribou Biosciences | Crispr Therapeutics vs. Verve Therapeutics |
| Alnylam Pharmaceuticals vs. ProQR Therapeutics BV | Alnylam Pharmaceuticals vs. Wave Life Sciences | Alnylam Pharmaceuticals vs. Blueprint Medicines Corp | Alnylam Pharmaceuticals vs. Apellis Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Complementary Tools
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |